Impact of antipsychotics and anticholinergics on autonomic modulation in patients with schizophrenia

Wei Lieh Huang, Li Ren Chang, Terry B J Kuo, Yu Hsuan Lin, Ying Zai Chen, Cheryl C H Yang

研究成果: 雜誌貢獻文章

22 引文 (Scopus)

摘要

Antipsychotics are associated with cardiovascular risk, but the relationship between their anticholinergic properties and cardiac function is not clear. We hypothesize that antipsychotics with a high muscarinic affinity (HMA) may reduce parasympathetic modulation, which should be observable by means of heart rate variability (HRV) measurement. We also assume that anticholinergics, which are commonly used in patients with schizophrenia to treat drug-induced parkinsonism, interact with antipsychotics, and this may also affect HRV. Fifty-five patients with schizophrenia were recruited into this study. Twenty-eight subjects used antipsychotics with an HMA and 27 subjects used antipsychotics with a low muscarinic affinity (LMA). Heart rate variability values between the patients on antipsychotics with HMA and those on antipsychotics with LMA were compared. Correlation and regression analysis were then performed to clarify the relationship between HMA, LMA, and HRV. The influence of anticholinergics was also assessed by correlation analysis. The HMA group showed significantly reduced low-frequency (LF) power, high-frequency (HF) power, total power (TP), and normalized LF (LF%) than the LMA group. Regression analysis supported the hypothesis that muscarinic affinity was related to LF (β =-0.447; P < 0.001), HF (β =-0.390; P = 0.002), and TP (β =-0.399; P = 0.001). The interaction between LMA and anticholinergic use also influenced LF% (β = 0.326; P = 0.006). In the LMA group, the use of anticholinergics was positively correlated with LF% and LF/HF. In the HMA group, after exclusion of the patients using anticholinergics, the equivalent dose of antipsychotics showed a negative correlation with HF. Our results suggest that the muscarinic affinity of antipsychotics affects both sympathetic and parasympathetic modulation and that anticholinergics interact with antipsychotics to influence HRV.
原文英語
頁(從 - 到)170-177
頁數8
期刊Journal of Clinical Psychopharmacology
33
發行號2
DOIs
出版狀態已發佈 - 四月 2013
對外發佈Yes

指紋

Cholinergic Antagonists
Cholinergic Agents
Antipsychotic Agents
Schizophrenia
Heart Rate
Regression Analysis
Parkinsonian Disorders

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

引用此文

Impact of antipsychotics and anticholinergics on autonomic modulation in patients with schizophrenia. / Huang, Wei Lieh; Chang, Li Ren; Kuo, Terry B J; Lin, Yu Hsuan; Chen, Ying Zai; Yang, Cheryl C H.

於: Journal of Clinical Psychopharmacology, 卷 33, 編號 2, 04.2013, p. 170-177.

研究成果: 雜誌貢獻文章

Huang, Wei Lieh ; Chang, Li Ren ; Kuo, Terry B J ; Lin, Yu Hsuan ; Chen, Ying Zai ; Yang, Cheryl C H. / Impact of antipsychotics and anticholinergics on autonomic modulation in patients with schizophrenia. 於: Journal of Clinical Psychopharmacology. 2013 ; 卷 33, 編號 2. 頁 170-177.
@article{087aa1139bbd45d290689ba20379a73e,
title = "Impact of antipsychotics and anticholinergics on autonomic modulation in patients with schizophrenia",
abstract = "Antipsychotics are associated with cardiovascular risk, but the relationship between their anticholinergic properties and cardiac function is not clear. We hypothesize that antipsychotics with a high muscarinic affinity (HMA) may reduce parasympathetic modulation, which should be observable by means of heart rate variability (HRV) measurement. We also assume that anticholinergics, which are commonly used in patients with schizophrenia to treat drug-induced parkinsonism, interact with antipsychotics, and this may also affect HRV. Fifty-five patients with schizophrenia were recruited into this study. Twenty-eight subjects used antipsychotics with an HMA and 27 subjects used antipsychotics with a low muscarinic affinity (LMA). Heart rate variability values between the patients on antipsychotics with HMA and those on antipsychotics with LMA were compared. Correlation and regression analysis were then performed to clarify the relationship between HMA, LMA, and HRV. The influence of anticholinergics was also assessed by correlation analysis. The HMA group showed significantly reduced low-frequency (LF) power, high-frequency (HF) power, total power (TP), and normalized LF (LF{\%}) than the LMA group. Regression analysis supported the hypothesis that muscarinic affinity was related to LF (β =-0.447; P < 0.001), HF (β =-0.390; P = 0.002), and TP (β =-0.399; P = 0.001). The interaction between LMA and anticholinergic use also influenced LF{\%} (β = 0.326; P = 0.006). In the LMA group, the use of anticholinergics was positively correlated with LF{\%} and LF/HF. In the HMA group, after exclusion of the patients using anticholinergics, the equivalent dose of antipsychotics showed a negative correlation with HF. Our results suggest that the muscarinic affinity of antipsychotics affects both sympathetic and parasympathetic modulation and that anticholinergics interact with antipsychotics to influence HRV.",
keywords = "anticholinergics, antipsychotics, heart rate variability, muscarinic affinity, schizophrenia",
author = "Huang, {Wei Lieh} and Chang, {Li Ren} and Kuo, {Terry B J} and Lin, {Yu Hsuan} and Chen, {Ying Zai} and Yang, {Cheryl C H}",
year = "2013",
month = "4",
doi = "10.1097/JCP.0b013e3182839052",
language = "English",
volume = "33",
pages = "170--177",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Impact of antipsychotics and anticholinergics on autonomic modulation in patients with schizophrenia

AU - Huang, Wei Lieh

AU - Chang, Li Ren

AU - Kuo, Terry B J

AU - Lin, Yu Hsuan

AU - Chen, Ying Zai

AU - Yang, Cheryl C H

PY - 2013/4

Y1 - 2013/4

N2 - Antipsychotics are associated with cardiovascular risk, but the relationship between their anticholinergic properties and cardiac function is not clear. We hypothesize that antipsychotics with a high muscarinic affinity (HMA) may reduce parasympathetic modulation, which should be observable by means of heart rate variability (HRV) measurement. We also assume that anticholinergics, which are commonly used in patients with schizophrenia to treat drug-induced parkinsonism, interact with antipsychotics, and this may also affect HRV. Fifty-five patients with schizophrenia were recruited into this study. Twenty-eight subjects used antipsychotics with an HMA and 27 subjects used antipsychotics with a low muscarinic affinity (LMA). Heart rate variability values between the patients on antipsychotics with HMA and those on antipsychotics with LMA were compared. Correlation and regression analysis were then performed to clarify the relationship between HMA, LMA, and HRV. The influence of anticholinergics was also assessed by correlation analysis. The HMA group showed significantly reduced low-frequency (LF) power, high-frequency (HF) power, total power (TP), and normalized LF (LF%) than the LMA group. Regression analysis supported the hypothesis that muscarinic affinity was related to LF (β =-0.447; P < 0.001), HF (β =-0.390; P = 0.002), and TP (β =-0.399; P = 0.001). The interaction between LMA and anticholinergic use also influenced LF% (β = 0.326; P = 0.006). In the LMA group, the use of anticholinergics was positively correlated with LF% and LF/HF. In the HMA group, after exclusion of the patients using anticholinergics, the equivalent dose of antipsychotics showed a negative correlation with HF. Our results suggest that the muscarinic affinity of antipsychotics affects both sympathetic and parasympathetic modulation and that anticholinergics interact with antipsychotics to influence HRV.

AB - Antipsychotics are associated with cardiovascular risk, but the relationship between their anticholinergic properties and cardiac function is not clear. We hypothesize that antipsychotics with a high muscarinic affinity (HMA) may reduce parasympathetic modulation, which should be observable by means of heart rate variability (HRV) measurement. We also assume that anticholinergics, which are commonly used in patients with schizophrenia to treat drug-induced parkinsonism, interact with antipsychotics, and this may also affect HRV. Fifty-five patients with schizophrenia were recruited into this study. Twenty-eight subjects used antipsychotics with an HMA and 27 subjects used antipsychotics with a low muscarinic affinity (LMA). Heart rate variability values between the patients on antipsychotics with HMA and those on antipsychotics with LMA were compared. Correlation and regression analysis were then performed to clarify the relationship between HMA, LMA, and HRV. The influence of anticholinergics was also assessed by correlation analysis. The HMA group showed significantly reduced low-frequency (LF) power, high-frequency (HF) power, total power (TP), and normalized LF (LF%) than the LMA group. Regression analysis supported the hypothesis that muscarinic affinity was related to LF (β =-0.447; P < 0.001), HF (β =-0.390; P = 0.002), and TP (β =-0.399; P = 0.001). The interaction between LMA and anticholinergic use also influenced LF% (β = 0.326; P = 0.006). In the LMA group, the use of anticholinergics was positively correlated with LF% and LF/HF. In the HMA group, after exclusion of the patients using anticholinergics, the equivalent dose of antipsychotics showed a negative correlation with HF. Our results suggest that the muscarinic affinity of antipsychotics affects both sympathetic and parasympathetic modulation and that anticholinergics interact with antipsychotics to influence HRV.

KW - anticholinergics

KW - antipsychotics

KW - heart rate variability

KW - muscarinic affinity

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84874936793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874936793&partnerID=8YFLogxK

U2 - 10.1097/JCP.0b013e3182839052

DO - 10.1097/JCP.0b013e3182839052

M3 - Article

AN - SCOPUS:84874936793

VL - 33

SP - 170

EP - 177

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 2

ER -